J D Boyer
Overview
Explore the profile of J D Boyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1010
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karuppuchamy T, Behrens E, Gonzalez-Cabrera P, Sarkisyan G, Gima L, Boyer J, et al.
Mucosal Immunol
. 2016 Apr;
10(1):162-171.
PMID: 27049060
The sphingosine-1-phosphate receptor-1 (S1P) agonist ozanimod ameliorates ulcerative colitis, yet its mechanism of action is unknown. Here, we examine the cell subsets that express S1P in intestine using S1P-eGFP mice,...
2.
Ramirez L, Arango T, Thompson E, Naji M, Tebas P, Boyer J
J Leukoc Biol
. 2014 Aug;
96(6):1055-63.
PMID: 25157027
HIV-1-infected subjects, despite control of viral replication with ART, have an altered immune cytokine/chemokine milieu. Changes in systemic cytokines and chemokines can alter immune responses. IP-10, in particular, has been...
3.
Mourant J, Bigio I, Boyer J, Johnson T, Lacey J, Bohorfoush Iii A, et al.
J Biomed Opt
. 2012 Sep;
1(2):192-9.
PMID: 23014685
No abstract available.
4.
Robinson T, Sidhu M, Pavlakis G, Felber B, Silvera P, Lewis M, et al.
J Med Primatol
. 2007 Aug;
36(4-5):276-84.
PMID: 17669216
Background: The cell mediated immune profiles following immunization with a recombinant DNA vaccine was assessed in the simian-human immunodeficiency virus (SHIV) and Macaque model. Earlier work demonstrated increased numbers of...
5.
Trillet-Lenoir V, Chapuis F, Touzet S, Barbier J, Freyer G, Gaudin J, et al.
Clin Oncol (R Coll Radiol)
. 2004 Jun;
16(3):196-203.
PMID: 15191007
Aims: Computed tomography (CT) is the reference technique for evaluating response to chemotherapy. The potential helpfulness of tumour markers is debated. Materials And Methods: From March 1997 to January 1999,...
6.
Boyer J, Chattergoon M, Muthumani K, Kudchodkar S, Kim J, Bagarazzi M, et al.
J Liposome Res
. 2003 Feb;
12(1-2):137-42.
PMID: 12604047
We studied the effects of first generation HIV-1 plasmid vaccines in 167 individuals. The vaccines were very well tolerated and induced helper T cell responses in most vaccine recipients. However,...
7.
Trillet-Lenoir V, Freyer G, Kaemmerlen P, Fond A, Pellet O, Lombard-Bohas C, et al.
Br J Radiol
. 2002 Dec;
75(899):903-8.
PMID: 12466256
Evaluation of tumour size modifications in response to treatment is a critical issue in the management of advanced malignancies. In 1981, the World Health Organization (WHO) established guidelines for tumour...
8.
Muthumani K, Kudchodkar S, Zhang D, Bagarazzi M, Kim J, Boyer J, et al.
Vaccine
. 2002 May;
20(15):1999-2003.
PMID: 11983262
Since the first reports of plasmid vaccines, there have been substantial changes made to the design of plasmid backbones, as well as to the antibiotic resistance markers chosen for clinical...
9.
Boyer J, Nath B, Schumann K, Curley E, Manson K, Kim J, et al.
Int J Parasitol
. 2002 Apr;
32(5):543-50.
PMID: 11943227
It is widely believed that a Th1 type CD4 response is critical for enhancement of CD8 immunity and for controlling HIV-1 infection. Th2 type responses, such as what might be...
10.
Sin J, Kim J, Chattergoon M, Ayyavoo V, McCallus D, Ugen K, et al.
Dev Biol (Basel)
. 2001 Nov;
104:187-98.
PMID: 11713819
These studies support the view that additional goals of enhancing DNA vaccine technology will probably be at several levels. The ability to deliver antigens more efficiently to professional APCs is...